Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06585007 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer

Name: Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer — clinical trial record (NCT06585007)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: MEDCARE

StatusRecruiting

PhasePhase 3

SponsorUniversitaire Ziekenhuizen KU Leuven

Started2023-12-19

View on ClinicalTrials.gov ↗

Universitaire Ziekenhuizen KU Leuven

296 trials monitored

See 3 trials at risk

Prostate Cancer

2,471 trials monitored

See 156 trials at risk

Evaluation of the impact of metastasis-directed therapy in patients with castration-refractory prostate cancer and a maximum of 5 progressive lesions.

Trial Details

NCT Number	NCT06585007
Lead Sponsor	Universitaire Ziekenhuizen KU Leuven
Conditions	Castration-resistant Prostate Cancer, Oligoprogressive
Enrollment	246 participants
Start Date	2023-12-19
Primary Completion	2029-01-20 (estimated)
Study Completion	2029-01-20 (estimated)
Updated on ClinicalTrials.gov	2024-09-05